A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Shares of Eli Lilly & Co. rose 3.38% to $1,062.19 Monday, on what proved to be an all-around grim trading session for the ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

BlackRock Health Sciences Trust is a Buy for income investors, offering an 8% yield, NAV discount, and resilient healthcare ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) will open a 44,000-square-foot life sciences facility in Philadelphia. The space will span the first and second floors 2300 Market Street, an eight-story, ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the ...